Incruse Ellipta (umeclidinium) / GSK - LARVOL DELTA

Late Breaking Abstract - A Phase III, Randomized, Multicentre, Active controlled study to evaluate Fluticasone Furoate, Umeclidinium and Vilanterol in Uncontrolled Asthma Management (ERS 2026) - "Aims and objectives: To assess efficacy and tolerability of a FDC of Fluticasone Furoate 200 mcg, Umeclidinium 62.5 mcg and Vilanterol 25 mcg compared with FDC of Indacaterol 150 mcg, Glycopyrronium 50 mcg and Mometasone furoate 160 mcg powder for inhalation in bronchial asthma Methods Adults patients with moderate-to-severe uncontrolled asthma were enrolled in the study. The FDC of FF/UME/VI was non-inferior to IND/GLY/MF in improving lung function (trough FEV₁) in uncontrolled asthma. Both treatments were well tolerated."

Clinical • Late-breaking abstract • P3 data • Asthma • Immunology • Respiratory Diseases

CP006-ASTHMA: Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma (clinicaltrials.gov) - P2 | N=150 | Completed | Sponsor: Shanghai Xin Huanghe Pharmaceutical Co., Ltd.

New P2 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators (clinicaltrials.gov) - P4 | N=72 | Recruiting | Sponsor: University of Tennessee Graduate School of Medicine | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study Comparing the Effectiveness and Safety of TQC3403 versus Anoro® in Patients with Chronic Obstructive Pulmonary Disease (ChiCTR) - P=N/A | N=408 | Completed | Sponsor: Shenzhen People's Hospital; Zhengda Tianqing Pharmaceutical Group Co., Ltd.

New trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Efficacy and Safety of Topical Anticholinergics in the Treatment of Primary Axillary Hyperhidrosis: A Systematic Review and Meta-analysis. (PubMed, Clin Drug Investig) - "Topical anticholinergic agents are effective for PAH treatment, with distinct efficacy and safety profiles. Although the available evidence is limited by the small number of trials, short follow-up durations, and heterogeneity in outcome reporting, these findings support the role of topical anticholinergic therapy as an effective non-invasive option for PAH."

Journal • Retrospective data • Review • Constipation • Dermatology • Gastroenterology • Gastrointestinal Disorder • Ophthalmology • Xerostomia

Meds from…GSK now offered through TrumpRx DTC platform (Fierce Pharma) - "GSK... is offering DTC discounts on several of its Ellipta inhalers...through the platform....GSK’s Anoro Ellipta comes with a 49% DTC discount. Arnuity Ellipta is between 51-54% lower than its list price through the platform, while the cash price for Incruse Ellipta is 55% lower."

Commercial • Chronic Obstructive Pulmonary Disease

A pragmatic, multicentre, placebo-controlled, 3-arm, double-blinded, randomised controlled trial, incorporating an internal pilot, to determine the role of bronchodilators in preventing exacerbations of bronchiectasis. (PubMed, Health Technol Assess) - "Twelve months, one puff daily of either dual therapy [55 μg umeclidinium (long-acting muscarinic antagonists) and 22 μg vilanterol (long-acting beta agonists)], triple therapy [dual therapy plus 92 μg fluticasone furoate (inhaled corticosteroid)] or matched placebo dry powder inhalers, randomised in a 2 : 2 : 1 ratio, respectively. These results underscore the importance of completing a large-scale trial of these therapies to help improve the understanding and best treatment for patients with bronchiectasis. This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number NIHR127460."

Journal • Asthma • Bronchiectasis • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

Obstructive Spirometric Index Predicts Lung Function Response to LAMA in asthma: A Post-Hoc Analysis of the CAPTAIN Trial (ERS 2025) - P3 | "AIM: To assess OSI's predictive value for response to the long-acting muscarinic antagonist (LAMA) umeclidinium (UMEC)... The OSI, which integrates FEV1 and FEV1/FVC, predicts lung function improvement with UMEC, whereas FEV ₁ alone does not. OSI may identify treatment opportunities. FUNDING: GSK/APQ/FRQS/NIHR (NCT02924688)."

Retrospective data • Asthma • Immunology • Respiratory Diseases

Impact of inhaled triple therapy on symptomatic tobacco-exposed individuals with normal spirometry (ERS 2025) - " In this investigator-initiated, interventional trial, symptomatic tobacco-exposed individuals with ≥10pack- year smoking history and FEV1/FVC>0.7 (intervention group) underwent evaluation, including quality-of-life assessments, lung function, computed tomography, and exercise capacity measurements at baseline and after 12 weeks of therapy with ICS(Fluticasone furoate 92mcg), LABA(Vilanterol 22mcg) and LAMA(Umeclidinium 55mcg). Inhaled triple therapy significantly reduces the burden of small airway disease and alleviates symptoms in symptomatic tobacco-exposed individuals with preserved FEV1/FVC ratio."

Clinical • Respiratory Diseases

Triple therapy versus dual inhaler therapy for moderate-to-severe asthma: an updated systematic review and meta-analysis. (PubMed, Ann Allergy Asthma Immunol) - "In patients with moderate-to-severe asthma, triple therapy, compared to dual therapy, reduces severe exacerbations in patients at high risk for future exacerbation with minimal harm."

Journal • Retrospective data • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

IgG4 Related Disease Presenting With an Inflammatory Pulmonary Mass (ATS 2025) - "His medications included Budesonide/Formoterol and Umeclidinium...It can be a progressive fibrotic process so systemic therapy should be considered (1). Corticosteroids are typically used (3) however there are steroid sparing options (3)."

Asthma • Fibrosis • Infectious Disease • Inflammation • Oncology • Pneumonia • Respiratory Diseases

Impact of Simultaneous Step-Up to High-Dose Fluticasone Furoate and Addition of Umeclidinium on a Clinical Remission Endpoint in Asthma: CAPTAIN Post Hoc Analysis (ATS 2025) - P3 | "This abstract is funded by: GSK (205715/NCT02924688) Rationale: Clinical remission (CR) is an ambitious and achievable treatment goal in asthma. Both increasing FF dose and adding UMEC contributed to improving clinical outcomes in patients with asthma. These results suggest that the greater odds of meeting the CR endpoint with FF/UMEC/VI 200/62.5/25 versus FF/VI 100/25 were mostly driven by the addition of UMEC. Although data over 52 weeks are needed to confirm achievement of CR, patients not yet considered for biologics with moderate-to-severe asthma uncontrolled on FF/VI 100/25 may gain greater benefits with simultaneous step-up to high-dose triple therapy versus increasing FF dose or adding UMEC alone."

Clinical • Retrospective data • Asthma • Immunology • Respiratory Diseases

Single-Inhaler Triple Therapy Is Useful for Achieving Clinical Remission in Patients With Bronchial Asthma by Improving Asthma Control Test Scores (ATS 2025) - "The Japan Asthma Society has proposed clinical remission (CR) as the treatment goal for bronchial asthma. Based on their medical records, bronchial asthma patients who were newly prescribed fluticasone furoate 200 / umeclidinium bromide / vilanterol trifenatate (FF (200) / UMEC / VI) at our hospital by the end of August 2024 were investigated. FF (200) / UMEC / VI can contribute to the achievement of CR in patients with bronchial asthma."

Clinical • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Long-acting muscarinic antagonists (LAMA) in asthma: What is the best strategy? (PubMed, Respir Med Res) - "However, eosinophil levels do not seem to predict the efficacy of LAMA. The role and long-term benefits of LAMA combined with biologic therapy in severe asthma remain uncertain, with more clinical data needed."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

The Role of Long-Acting Muscarinic Antagonists (LAMA) in Severe Asthma (KATRDIC 2024) - "And also, the addition of another LAMA (Umeclidinium, Glycopyrronium) improved lung function, reduced symptoms and exacerbation rate of patients with severe asthma...In conclusion, LAMAs offer a promising therapeutic option for patients with severe asthma, particularly in the context of persistent symptoms despite standard treatments. Ongoing research and clinical experience continue to refine our understanding of their optimal use and long-term benefits in this challenging patient population who have uncontrolled asthma symptoms."

Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Drug-associated glaucoma: A real-world study based on the Food and Drug Administration adverse event reporting system database. (PubMed, Clin Exp Ophthalmol) - "Preventing drug-associated glaucoma is more effective than treatment. Identifying the risk and drug-induced times of systemic and ophthalmic drugs can reduce occurrence risk. Clinical practitioners should be vigilant and inform patients of these risks."

Adverse events • Journal • Real-world • Real-world evidence • Glaucoma • Ophthalmology

In Vitro Analysis of Aerodynamic Properties and Co-Deposition of a Fixed-Dose Combination of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate. (PubMed, Pharmaceutics) - "Spatial distribution and abundance of ICS/LABA/LAMA in the same cascade levels were closely comparable, and the aerosol particles were able to reach the small aerosol-sized cascades at the lower levels to some extent."

Journal • Preclinical • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

THE ASTHMATIC SPECTRUM: ABPA TO CHRONIC PULMONARY ASPERGILLOSIS IN ADULTS (CHEST 2024) - "He had previously been stable on a regimen of prednisone, fluticasone, umeclidinium, and omalizumab along with Mucinex and albuterol as needed...Treatment with voriconazole, levofloxacin, inhaled tiotropium, and budesonide led to remarkable recovery, and the patient currently remains stable with follow-up... Preventing further lung damage involves starting antifungal therapy and minimizing corticosteroid use, as increased corticosteroid treatment may compromise the immune response and promote Aspergillus growth."

Clinical • Allergic Bronchopulmonary Aspergillosis • Asthma • Bronchiectasis • Chronic Cough • Chronic Obstructive Pulmonary Disease • Cough • Immunology • Otorhinolaryngology • Pain • Pulmonary Disease • Respiratory Diseases

Interaction between fluticasone furoate and umeclidinium in passively sensitised isolated human airways. (PubMed, Pulm Pharmacol Ther) - "This study suggests that higher doses of FF might be necessary in a fixed dose combination to achieve optimal synergistic bronchodilation with UME. Future research should focus on clinical trials to confirm these findings and explore the molecular mechanisms underlying these interactions, potentially improving personalized asthma therapy."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

DECIPHERING TRACHEAL DEFORMITIES VS COPD ON PULMONARY FUNCTION TESTING (CHEST 2024) - "He has been compliant with maximum dose budesonide-formoterol, umeclidinium, dupilumab infusions, and chronic prednisone 20 mg daily. While both COPD and tracheal deformities can exhibit flattening of the expiratory limb on flow-volume loops, the latter can flatten the inspiratory limb from fixed airflow limitation. Structural airway deformities can exacerbate pre-existing obstructive lung disease and may benefit from dilation and further surgical interventions. Interpretation of flow-volume loops should be done in conjunction with clinical findings, imaging studies, and PFTs to accurately diagnose and differentiate between these conditions."

Cardiovascular • Chronic Obstructive Pulmonary Disease • Immunology • Pain • Respiratory Diseases

Clinical benefits with Fluticasone furoate/Umeclidinium/Vilanterol therapy for COPD: post hoc subgroup analysis of ELLITHE study (ERS 2024) - "In COPD patients of this ELLITHE subanalysis, odSITT improved CAT score independent of specified baseline criteria. Despite overlap in response, individual outcome assessments are necessary to fully comprehend differential benefits of real-world odSITT beyond exacerbations."

Clinical • Retrospective data • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Clinically Relevant β2-agonists Induce and Augment Rhinovirus-induction of Asthma-relevant Pro-inflammatory Mediators in Human Bronchial Epithelial Cells (ATS 2024) - " BEAS-2B BECs were stimulated with SABAs (fenoterol, salbutamol), LABAs (formoterol, salmeterol), ultra-LABAs (indacaterol, olodaterol, vilanterol), short-acting (ipratropium) or long-acting (tiotropium, aclidinium, umeclidinium) muscarinic antagonists, at concentrations 0. β2-agonists upregulate BEC production of asthma-relevant pro-inflammatory mediators, while muscarinic antagonists do not. β2-agonists also augment RV-induction of disease-relevant mediators. Corticosteroid co-administration abolishes these pro-inflammatory effects."

Clinical • Late-breaking abstract • Asthma • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • BDNF • IL6

Severe Bullous Emphysema Induced by Crack Cocaine Use (ATS 2024) - "The patient was started on Methylprednisolone 40 mg IV every twelve hours, Ceftriaxone 2 g IV daily, and Doxycycline 100 mg every twelve hours...He was prescribed Umeclidinium bromide / Vilanterol as maintenance therapy...BE is frequently asymptomatic and discovered by chance on imaging. Ensuring correct diagnosis and treatment will improve the outcomes in this patient population."

Cardiovascular • Cough • Fatigue • Hematological Disorders • Hypertension • Infectious Disease • Inflammation • Pneumonia • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Septic Shock • Transplantation

Restrictions in Diagnosing Lung Diseases; The Importance of Broad Differential (ATS 2024) - "Case 1: A 63-year-old female, smoker was initially treated for COPD with fluticasone furoate/umeclidinium/vilaterol inhaler and albuterol as needed...He was also treated with Nintedanib...In our case series, we emphasize the critical need for accurate COPD diagnosis using appropriate diagnostic tools to diagnose the other lung diseases. This approach is essential to ensure that patients receive the correct diagnosis and subsequent treatment, ultimately improving their overall health and quality of life."

Chronic Obstructive Pulmonary Disease • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • Transplantation

Triple Therapy and Clinical Control in B+ COPD Patients: A Pragmatic, Prospective, Randomized Trial. (PubMed, Arch Bronconeumol) - "The ANTES B+ study is the first to: (1) explore the efficacy and safety of triple therapy in a population of B+ COPD patients and (2) use a composite index (CC) as the primary result of a COPD trial."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases